Cancer Funding - November 3, 2020

Nov 3, 2020, 09:56 AM by Melodi Moore
AACR

Breast Cancer Research Foundation-AACR Career Development Awards

Basic, translational, clinical, epidemiological, population health, and/or community-based cancer research projects designed to accelerate the discovery, development, and application of new agents to treat breast cancer.  Must be designed to promote diversity and inclusion represent a focused effort to encourage and support investigators from diverse backgrounds that are under-represented in cancer research and to foster their career advancement and  build a more diverse and inclusive future for breast cancer research. Eligibility is limited to members of racial or ethnic groups that have been shown to be underrepresented in the biomedical workforce who are junior faculty who, at the start of the grant term, will have completed their most recent doctoral degree or medical residency within the past 11 years.

Application Deadline:   December 18 @ 1:00 PM (EST)


cdmrp_logo
FY20 Prostate Cancer Research Program
Physician Research Award

The FY20 PCRP Physician Research Award supports a mentored research experience to prepare physicians with clinical duties and/or responsibilities for productive careers in prostate cancer research. The mentored physician is considered the Principal Investigator (PI) of the application. 

This award emphasizes equally the quality of the proposed research project and the career development of the PI, which should prepare physicians for careers in basic, population science, translational, or clinical prostate cancer research. All applications for the FY20 PCRP Physician Research Award are to be written by the PI, with appropriate direction from the Mentor(s).

Letters of Intent Due:  December 15, 2020

FY20 Rare Cancers Research Program
Concept Award

The FY20 RCRP Concept Award supports highly innovative, untested, potentially groundbreaking novel concepts in rare cancers. The Concept Award is not intended to support an incremental progression of an already established research project; instead, it allows Principal Investigators (PIs) the opportunity to pursue serendipitous observations. Preliminary data are not required. This award mechanism supports high-risk studies that have the potential to reveal entirely new avenues for investigation. Applications must describe how the new idea will enhance the existing knowledge of rare cancers or develop an innovative and novel course of investigation. Research completed through a Concept Award may generate sufficient preliminary data to enable the PI to prepare an application for future research.

Letters of Intent Due:  November 12, 2020

Idea Development Award

The FY20 RCRP Idea Development Award mechanism promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation. This award supports conceptually innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress toward eradicating deaths and suffering from rare cancers. Applications should include a well formulated, testable hypothesis based on strong scientific rationale.

Preliminary data with disease-specific rationale (including correlatives in existing trials) to support the feasibility of the research hypotheses and research approaches are required; however, these data do not necessarily need to be derived from studies of the proposed rare cancer type(s)/sub-type(s) under study

Letters of Intent Due:  November 12, 2020

Resource and Community Development Award

The FY20 RCRP RCDA supports the development of resources to advance the field of rare cancers research and ultimately improve outcomes for individuals with rare cancers. Major gaps in patient care of rare cancers include lack of communication and dissemination strategies for rare cancer research and clinical findings within communities; lack of therapeutics and mechanistic studies to inform treatment development; lack of research and clinical resources including patient tissues, cell, and tumor models; and lack of infrastructure for sharing data and other resources.

The intent of this funding opportunity is to develop platforms that can share resources and knowledge pertaining to available models, molecular pathways, and therapeutic approaches to facilitate collaboration and information sharing among stakeholders such as researchers, patients, caregivers, clinicians, and other members of the rare cancers community.

Letters of Intent Due:  November 12, 2020

PreAnnouncement - FY21 Breast Cancer Research Program

While not announced yet, the CDMRP has released Anticipated Funding Opportunities for the FY21 Breast Cancer Research Program (BCRP).  This allows those interested in this type of research to prepare for the mechanism and amount of funding they will request.  Applications submitted to the FY21 BCRP must address one or more of the following overarching challenges:

  • Prevent breast cancer (primary prevention)
  • Identify determinants of breast cancer initiation, risk, or susceptibility
  • Distinguish deadly from non-deadly breast cancers
  • Conquer the problems of overdiagnosis and overtreatment
  • Identify what drives breast cancer growth; determine how to stop it
  • Identify why some breast cancers become metastatic
  • Determine why/how breast cancer cells lie dormant for years and then re-emerge; determine how to prevent lethal recurrence
  • Revolutionize treatment regimens by replacing them with ones that are more effective, less toxic, and impact survival
  • Eliminate the mortality associated with metastatic breast cancer

Click on the pre-announcement link to learn about mechanisms and funding levels (subject to Congressional appropriation).


Cancer Research Institute

Postdoctoral Fellowship

The CRI Irvington Postdoctoral Fellowship Program (Special Call) provides critical financial support and continued career training to the most promising young scientists in basic and tumor immunology as part of our lifesaving work in cancer immunotherapy research.  In collaboration with the Fibrolamellar Cancer Foundation, CRI has secured limited funding for additional postdoctoral fellowships for candidates whose projects are focused on understanding the immunological response to fibrolamellar carcinoma and accelerating the development of effective immunotherapy treatments for this rare, aggressive liver cancer that occurs predominantly in otherwise healthy adolescents and young adults.

Application Deadline:  April 1, 2021


Conquer Cancer

Advanced Clinical Research Award (ACRA) for Diversity and Inclusion

Awards will be given to mid-career investigators who are members of racial and/or ethnic groups historically underrepresented in academic medicine and wish to conduct original breast cancer research not currently funded.  Must be a physician (MD, DO, or international equivalent) who is in the fourth to ninth year of a full-time, primary faculty appointment in a clinical department at an academic medical institution at the time of grant submission and a member of ASCO.

Letter of Intent Deadline:  November 30, 2020


CPRIT Innovations Save the Date

Dissemination of CPRIT-Funded Cancer Control Interventions

Seeks to fund projects that will facilitate the dissemination and implementation of successful CPRIT-funded, evidence-based cancer prevention and control interventions across Texas. The proposed project should be able to develop one or more "products" based on the results of the CPRIT-funded intervention.

Application Deadline:  February 10, 2021

Evidence-Based Cancer Prevention Services

Seeks to fund projects that will deliver evidence-based cancer prevention and control clinical services. Priority will be given to projects that propose to address CPRIT areas of emphasis and serve areas of the state not well addressed by current CPRIT funded projects. Only proposals for new projects or expansion of currently/previously funded projects focused on obesity control/healthy living or survivor care are eligible.  Eligible applications must include the delivery of services to nonmetropolitan (rural) and medically underserved counties in the state.

Application Deadline:  February 10, 2021

Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations

Seeks to support the coordination and expansion of evidence based services to prevent cancer in underserved populations who do not have adequate access to cancer prevention interventions and health care, bringing together networks of public health and community partners to carry out programs tailored for their communities. Projects should identify cancers that cause the most burden in the community and use evidence-based models shown to work in similar communities to prevent and control these cancers.

Application Deadline:  February 10, 2021

Tobacco Control and Lung Cancer Screening

Seeks to fund programs on tobacco prevention and cessation, as well as screening for early detection of lung cancer. Through release of this RFA, CPRIT’s goal is to stimulate more programs across the state, thereby providing greater access for underserved populations and reducing the incidence and mortality rates of tobacco-related cancers.

Application Deadline:  February 10, 2021

Recruitment of Established Investigators (Revised 10/26/2020)

Recruits outstanding senior research faculty with distinguished professional careers and established cancer research programs to academic institutions in Texas.

Recruitment of First-Time, Tenure-Track Faculty Members (Revised 10/26/2020)

Supports very promising emerging investigators, pursuing their first faculty appointment in Texas, who have the ability to make outstanding contributions to the field of cancer research.

Recruitment of Rising Stars (Revised 10/26/2020)

Recruits outstanding early-stage investigators to Texas, who have demonstrated the promise for continued and enhanced contributions to the field of cancer research.

Continuous Submission


Damon Runyon Logo

***Applicants can apply for only one of the following.***

Damon Runyon Postdoctoral Fellowship Award

The Damon Runyon Fellowship Award supports the training of the brightest postdoctoral scientists as they embark upon their research careers. This funding enables them to be mentored by established investigators in leading research laboratories across the country.

Applicants must have a new sponsor (joined lab on or after grant deadline) and their degree must be conferred between September 15, 2019 - March 15, 2021

Application Deadline:   March 15, 2021

Damon Runyon-Sohn Pediatric Cancer Fellowship Award

The Damon Runyon Cancer Research Foundation has joined together with the Sohn Conference Foundation, dedicated to curing pediatric cancers, to establish the Damon Runyon-Sohn Pediatric Cancer Fellowship Award. This award provides funding to basic scientists and clinicians who conduct research with the potential to significantly impact the prevention, diagnosis or treatment of one or more pediatric cancers.

Candidates must apply for the fellowship under the guidance of a Sponsor—a scientist (tenured, tenure-track or equivalent position) capable of providing mentorship to the Fellow. Degrees must have been conferred between September 15, 2019 - March 15, 2021

Application Deadline:  March 15, 2021

Physician-Scientist Training Award

In an effort to confront the crisis arising from a growing dearth of physician-scientists, Damon Runyon wishes to encourage more physicians to pursue research careers. To do so, the Foundation established a program designed to recruit outstanding U.S. Specialty Board eligible physicians into cancer research careers by providing them with the opportunity for a protected research training experience under the mentorship of a highly qualified and gifted mentor after they have completed all of their clinical training. The goals are a) to transform these individuals into the highest quality physician-scientists, capable of conducting research that has the potential to transform the diagnosis, treatment and/or prevention of cancer and b) to eliminate the financial disincentive to entering this career path.

Application Deadline: December 1, 2020


NASA Logo
NASA models the risk of space radiation-induced health decrements including cancer, cardiovascular disease, and central nervous system damage to inform human exploration missions including International Space Station missions, future lunar missions (Artemis), and future missions to mars. An accurate understanding of the health risks associated with space radiation exposure are required to inform mission planning and post-mission health care. Risk models rely on understanding radiation-induced disease through epidemiological studies which quantify the risk in human cohorts. The epidemiological evidence is supplemented with knowledge gained through ground-based radiobiology experiments and limited spaceflight experiments. Due to the small number of astronauts with appreciable space radiation exposures, risks are scaled from terrestrial radiation exposure using models to account for the fundamental differences between terrestrial and space radiation exposures. The primary focus of this work is the development of these scaling models along with the associated computational framework used to determine the risk and associated uncertainties. Currently, NASA has an existing space radiation-induced cancer risk model with active research in all components of that model. Work is currently ongoing to develop a space radiation-induced cardiovascular risk model and to understand the basic risks of space radiation to the central nervous system. There is also interest in ensemble modeling of risk for use in the space radiation problem.

Contact Dr. Ryan Norman ryan.b.norman@nasa.gov directly for details about this opportunity.


Pancreatic Cancer Action Network

2021 Pancreatic Cancer Action Network Career Development Award

Supports junior faculty to conduct pancreatic cancer research and establish successful career paths in the field. Proposed research may be basic, translational, clinical or epidemiological in nature and must have direct applicability and relevance to pancreatic cancer. Special consideration will be given to understudied areas in pancreatic cancer research.

Application deadline: November 20, 2020


Rivken Center

Scientific Scholar Awards in ovarian cancer research

Scientific Scholar Awards are intended to assist promising laboratory and clinical scientists in pursuing a career as an independent investigator in ovarian cancer research.  Potential candidates will have an MD, PhD, or equivalent degree with career goals focused on ovarian cancer. Clinicians will have completed their residency. Candidates should be at the postdoc/fellow, instructor, research assistant, or assistant professor level with no more than 3-4 years in any of these positions. Established, outstanding scientists without prior focus in ovarian cancer but looking to focus in this disease area are also encouraged to apply.

Application Deadline:           December 1 @ 5:00 PM (EST)